Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00793975 · ClinicalTrials.gov registry record · Phase 1
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00793975 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 37 participants.
The verdict
NCT00793975, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.
Interventions
- BIOLOGICAL IMC-1121B
- BIOLOGICAL 1121B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00793975
The ClinicalTrials.gov registry entry for NCT00793975 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMC-1121B is the first listed.
NCT00793975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00793975 about?
NCT00793975 is a clinical study titled "Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy". The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.
What is the current status of trial NCT00793975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2005-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00793975?
The interventions under investigation include: IMC-1121B (BIOLOGICAL), 1121B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00793975?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.